1.
Benefits and risks of rapid initiation of antiretroviral therapy
by Ford, Nathan
AIDS (London), 2018, Vol.32 (1), p.17-23
2.
Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population
by Gueler, Aysel
AIDS (London), 2017, Vol.31 (3), p.427-436
3.
The future role of CD4 cell count for monitoring antiretroviral therapy
by Ford, Nathan, PhD
The Lancet infectious diseases, 2015, Vol.15 (2), p.241-247
4.
Time to overcome pretreatment HIV drug resistance
by Yerly, Sabine
The Lancet infectious diseases, 2018, Vol.18 (3), p.239-240
5.
Adverse events of raltegravir and dolutegravir
by Elzi, Luigia
AIDS (London), 2017, Vol.31 (13), p.1853-1858
6.
Bone health in HIV and hepatitis B or C infections
by Biver, Emmanuel Emmanuel
Therapeutic advances in musculoskeletal disease, 2016, Vol.9 (1), p.22-34
7.
Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial
by Bonnet, Maryline, Dr
The Lancet infectious diseases, 2013, Vol.13 (4), p.303-312
8.
Improving treatment outcome for children with HIV
by Calmy, Alexandra L
The Lancet (British edition), 2011, Vol.377 (9777), p.1546-1548
9.
Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa
by Ciaffi, Laura
AIDS (London), 2015, Vol.29 (12), p.1473-1481
10.
Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring
by Keiser, Olivia
AIDS (London), 2009, Vol.23 (14), p.1867-1874
11.
Hyaluronic Acid Filler in HIV-Associated Facial Lipoatrophy: Evaluation of Tissue Distribution and Morphology with MRI
by Becker, Minerva
Dermatology (Basel), 2015, Vol.230 (4), p.367-374
12.
Biomarkers and Electrocardiographic Evidence of Myocardial Ischemia in Patients With Human Immunodeficiency Virus Infection
by Gupta, Mihir, BA
The American journal of cardiology, 2013, Vol.111 (5), p.760-764
13.
Clinical update: adverse effects of antiretroviral therapy
by Calmy, Alexandra
The Lancet (British edition), 2007, Vol.370 (9581), p.12-14
14.
High prevalence of physical inactivity among patients from the Swiss HIV Cohort Study
by Schäfer, Juliane
AIDS care, 2017, Vol.29 (8), p.1056-1061
15.
Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis
by FORD, Nathan
AIDS (London), 2011, Vol.25 (18), p.2301-2304
16.
Outcomes of Antiretroviral Therapy in the Swiss HIV Cohort Study: Latent Class Analysis
by Keiser, Olivia
AIDS and behavior, 2011, Vol.16 (2), p.245-255
17.
Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis
by Ford, Nathan
AIDS (London), 2014, Vol.28 Suppl 2, p.S123-S131
18.
Viral load monitoring in resource-limited settings: a medical and public health priority
by Ford, Nathan
AIDS (London), 2012, Vol.26 (13), p.1719-1720
19.
HIV and Ebola virus: two jumped species but not two of a kind
by Calmy, Alexandra
AIDS (London), 2015, Vol.29 (13), p.1593-1596
20.
Cognitive dysfunction in HIV patients despite long-standing suppression of viremia
by SIMIONI, Samanta
AIDS (London), 2010, Vol.24 (9), p.1243-1250
